Nancy Harrison
Role: Fellow
Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Stream: Advanced Therapies
Nancy Harrison is a nationally recognized life sciences builder and investor with almost 30 years of experience as sector innovator and leader. Nancy is a venture partner with Amplitude Ventures.
Nancy previously spent 11 years as co-founder, chief business officer, and president with MSI Methylation Sciences, which grew from start-up to phase II clinical trials for one of its drugs, having raised over USD$70M during her tenure. Prior to her time at MSI, Nancy spent 14 years as a senior vice president and partner with Ventures West Management where she led the life sciences portfolio, growing it from zero to over 30 per cent of Venture West’s over investments. She helped lead Venture West’s transformation from $90M assets under management in eight historical funds to over $800MM AUM during her tenure.
Outside of the boards Nancy sits on behalf of Amplitude, she also serves on the boards and is an advisor for several companies and not-for-profits the including BC Genome I2 venture fund, BioteCanada advisory board for start-up companies, and is a fellow with the Creative Destruction Lab – West.
With both an MBA from McGill and an engineering degree from Queens, Nancy is a recipient of the 2020 Milton Wong Leadership Award from Life Science BC, the 2020 PEAK Award for Excellence in Leadership from the Association of Women in Finance, was named CDL-West Fellow of the Year in 2019 and has previously been named to Globe & Mail’s Top 40 under 40 in Canada.